BPC-157
Day 1 · Free base + acetate
Favorable recommendation
Both form-level questions received the same favorable tally.
- 8
- Yes
- 6
- No
- 1
- Abstain
Live coverage · July 23–24, 2026
One clear view of the FDA webcast, the 14 Section 503A voting questions, and every verified result as it lands.
Updated July 23 after the TB-500 vote
Verified from FDA webcast and meeting documents
Results board
Day 1 · Free base + acetate
Favorable recommendation
Both form-level questions received the same favorable tally.
Day 1 · Free base + acetate
Favorable recommendation
The committee delivered a favorable recommendation.
Day 1 · Free base + acetate
Favorable recommendation
The committee delivered another favorable 8–6–1 result.
Day 1 · Free base + acetate
Awaiting result
Awaiting a verified form-level result.
Day 2 · Free base + acetate
Awaiting result
Scheduled for Friday morning.
Day 2 · Free base + acetate
Awaiting result
Scheduled for Friday morning.
Day 2 · Free base + acetate
Awaiting result
Scheduled for Friday afternoon.
What moved the room
The testimony behind two of Thursday’s favorable recommendations.
BPC-157 · real-world record
Dr. Alex Tatem presented aggregated BPC-157 use with no clear attributable adverse safety signal.
Watch the testimonyTB-500 · testimony
Tatem connected full-length thymosin beta-4 trials, nearly 190,000 compounded vials, no serious complaints, and no human adverse-event cases found in FDA’s searches.
Watch Tatem’s caseRestoring Category 1 would move demand away from grey-market research products and under regulated compounding oversight.
What happens next
BPC-157, KPV, and TB-500 now move forward for FDA consideration. The federal process still has to update the Section 503A Bulks List.
FDA is streaming the July 2026 PCAC meeting on YouTube. The July 23 and July 24 official webcasts are linked directly from this tracker.
The July 2026 PCAC peptide agenda covers BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Epitalon, and Semax in free-base and acetate forms.
BPC-157 free base, BPC-157 acetate, KPV, and TB-500 received favorable committee results on July 23. This tracker keeps the remaining peptide votes together as they are reported.
The July 24 PCAC meeting starts at 8 a.m. Eastern and covers emideltide (DSIP), Epitalon, and Semax.
Yes. The same official FDA YouTube links remain available for replay after each PCAC livestream ends.
PCAC stands for Pharmacy Compounding Advisory Committee, the FDA advisory committee discussing the Section 503A Bulks List peptide nominations.
Coverage continues Friday